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Abstract  Triple  negative  breast  cancer  (TNBC)  is  a  subtype  of  breast  cancer  (BC)  with  a  hetero-
geneous nature  that  stains  negatively  for  estrogen  receptor  (ER),  progesterone  receptor  (PR)
and human  epidermal  growth  factor  2  (HER2)  during  immunohistochemistry.  Approximately
15--20% of  all  cases  of  breast  cancer  are  triple  negative  phenotypes.  Compared  to  patients  with
hormone receptor-positive  cancer,  TNBC  patients  are  typically  younger  (<50  years),  African
American,  and  have  a  high  incidence  of  mutations  in  BRCA1/2  genes.  To  date,  not  a  single  tar-
geted therapy  has  been  approved  for  TNBC  treatment,  and  cytotoxic  chemotherapy  remains
as the  standard  systemic  treatment,  meaning  that  TNBC  is  an  aggressive  subtype  of  breast
cancer with  a  poor  prognosis.  In  this  review,  the  literature  search  was  done  up  to  date  on
which gene  expression  proﬁle  of  TNBC  has  been  analyzed  in  order  to  identify  the  consensus
on molecular  mechanisms  involved  in  carcinogenesis  and/or  the  prognostic  markers  of  the
disease. In  conclusion,  these  studies  have  reported  that  TNBC  is  composed  of  several  clus-
ters or  genomic  signatures  as  basal  keratins.  They  have  also  reported  on  their  proliferation,
luminal/basal  apocrine,  regulatory  interferon,  immune  cells/immunoglobulin  related  to  stem
cells, epithelial-mesenchymal,  androgen  receptor  and  angiogenesis.  However,  not  all  research
groups have  reported  reproducible  results.  This  conﬁrms  the  heterogeneous  nature  of  TNBC
and the  need  for  research  on  uniform  selection  criteria.  However,  these  discoveries  have  led
to the  proposal  of  new  treatments,  such  as  the  addition  of  platinum  salts,  new  combinations
of therapeutic  agents,  some  targeted  therapies  such  as  PARP  inhibitors,  and  PI3K  and  androgen
antagonists.  There  is  no  doubt  that  a  better  understanding  of  the  nature  of  TNBC  will  allow
individualized  and  more  effective  therapies.
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reast  cancer  (BC)  is  the  main  cause  of  death  by  cancer
mong  women,  and  represents  30%  of  all  new  cancer  cases
n  the  Caucasian  population.  A  woman  living  in  the  United
tates  has  a  12.3%  (1  in  every  8)  risk  of  being  diagnosed  with
reast  cancer.1 According  to  the  World  Health  Organization,
.67  million  new  cases  were  registered  worldwide  in  2012.2
n  Mexico,  BC  is  also  the  ﬁrst  place  in  malignant  neoplasia
ncidence  among  women.  It  represents  11.34%  of  all  cancer
ases,  with  a  global  increase  of  approximately  1.5%  annually.
owever,  in  emerging  countries  this  increase  is  up  to  5%.3
Despite  having  the  same  origin  tissue,  BC  represents  a
eterogeneous  cancer  group  with  complex  biological  behav-
or  and  a  great  clinical  variability.  Over  the  last  10  years,
xtensive  research  at  a  molecular  and  genetic  level  has  been
onducted  in  order  to  sub-type  these  BCs.  This  has  permitted
he  determination  of  clinical,  pathological  and  molecular
ariables,  to  select  treatment  modalities  and  forecast,  in
ome  cases,  the  evolution  of  the  disease  at  the  moment  of
iagnosis.4
reast cancer classiﬁcation
n  the  traditional  way  the  most  important  information  that
athologists  gave  oncologists,  respect  to  the  classiﬁcation  of
reast  cancer,  included  the  status  of  the  nodules  and  tumor
ize,  histological  grade  and  standard  immunohistochemistry
ests  (IHC)  status  of  hormone  receptors:  estrogen  receptor
ER)  and  progesterone  receptor  (PR)  (Fig.  1).
Later  on,  in  the  era  of  trastuzumab,  information  on  the
mpliﬁcation  status  of  the  human  epidermal  growth  factor
eceptor  2  gene  (HER2)  became  routine.  Combining  all  these
arameters,  it  was  possible  to  classify  patients  as  high  or  low
isk.  There  were  however  a  group  of  patients  who  were  in  an
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igure  1  Breast  cancer  classiﬁcation  according  to  immunohistoche
HC and  microarray  expression  methods  (gene  signatures).  ER,  estr
rowth receptor  2;  CK,  cytokeratin;  EGFR,  growth  factor  receptor.G.I.  Uscanga-Perales  et  al.
ntermediate  category  that  could  not  be  classiﬁed  between
hese  two  groups.  Results  showed  that  15%  of  the  patients
lassiﬁed  as  low  risk  had  relapsed  or  died  due  to  a  very
ggressive  disease.  And  patients  classiﬁed  as  high  risk,  sur-
risingly  10--15%  had  a  favorable  response.  All  those  results
ed  to  the  conclusion  that  the  method  of  classiﬁcation  was
ot  very  appropriate.
Thus,  based  only  on  standard  IHC  directed  at  cellular
arkers  that  reﬂect  the  availability  of  targeted  therapies,
reast  cancer  can  also  be  classiﬁed  into  three  main  groups:
a)  homone  sensitive  (ER  or  PR  positive),  (b)  HER2  positive,
ensitive  to  trastuzumab  or  (c)  triple  negative  breast  can-
er  (TNBC),  deﬁned  by  the  absence  of  ER,  PR  and  HER2
mpliﬁcation.5--8
No  targeted  treatment  is  available  for  TNBT  and
hemotherapy  remains  the  best  therapeutic  option.  How-
ver,  in  the  case  of  recurrence  or  chemoresistance,
herapeutic  options  are  very  limited.9
Subsequently,  in  the  late  90s,  when  platforms  for
enomic  studies  were  available,  IHC  methods  coupled  with
omplementary  DNA  (cDNA)  microarray  technology,  allowed
or  a  more  extensive  BC  classiﬁcation  and  were  able  to
eﬁne  four  different  BC  subgroups,  which  differ  in  prognosis
nd  targets:  (a)  luminal  A  --  positive  to  ER  and  PR,  negative
o  the  ampliﬁcation  of  HER2,  with  a  low  proliferation  index
Ki-67  <  14%);  (b)  luminal  B  --  ER  positive,  HER2  positive  or
egative,  high  proliferation  index  (Ki-67  >  14%),  negative  or
ow  positive  PR;  (c)  positive  for  HER2  --  overexpressed  or
mpliﬁed  HER2,  negative  ER  and  PR;  (d)  basal-like  or  TNBC,
lso  deﬁned  by  the  absence  of  ER,  PR  and  HER2  ampliﬁca-
ion.  However,  this  last  assumption  is  not  strictly  accurate
ue  as  not  all  basal-like  tumors  are  completely  TNBC.10,11This  classiﬁcation  is  based  on  the  consideration  that  there
re  two  cell  types  in  the  mammary  gland,  luminal  cells  and
asal  cells.  These  two  cell  types  can  be  differentiated  by
HC  tests  as  luminal  cells,  which  express  ER  and  PR  and  that
ication
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are  positive  for  keratins  8/18,  while  basal  cells  are  positive
for  keratins  5/6  and  17.12,13
Because  of  the  cost  involved  in  utilizing  microarray  tech-
nology  in  the  clinic,  the  most  employed  technique  for  BC
classiﬁcation  remains  IHC  and  FISH.6,8,14
Between  60%  and  70%  of  all  breast  cancers  correspond
to  positive  ER  and  PR  subtypes,6 which  usually  respond  to
targeted  ER  therapy,  such  as  selective  ER  modulators  (i.e.
tamoxifen,  or  aromatase  inhibitors)  which  reduce  serum
estrogen  concentrations.  Around  15--20%  of  BCs  amplify  or
overexpress  the  HER2  oncogene.  This  type  of  cancer  is
associated  with  an  incorrect  prognosis  and  the  treatments
speciﬁcally  aimed  at  HER2  (i.e.  trastuzumab)  have  greatly
improved  results  in  women  with  BC  HER2+.15
Prognostic value of genomic signatures in BC
Despite  the  fact  that  they  have  not  completely  turned
into  routine  methods,  genomic  methods  have  been  used
in  research  studies  with  the  purpose  of:  (a)  getting  a  bet-
ter  understanding  of  the  nature  of  these  variations  of  BC;
(b)  stratifying  patients  through  assessment  of  the  evolution
of  the  disease  (evaluating  clinical  pathological  character-
istics),  and  (c)  understanding  the  possible  response  of  the
patient  to  treatment  (in  relationship  with  ER,  PR,  HER2  and
the  proliferation  rate).5,16
Through  global  expression  analysis  with  microarrays,  the
identiﬁcation  of  gene  groups  (genomic  signatures)  has  been
possible,  which  allow  us  to  estimate  risk  of  recurrence  of  the
disease  and/or  predict  the  response  to  adjuvant  therapy  in
BC  patients  in  the  early  stages.17--20 Some  of  these  genomic
signatures  have  been  validated  in  large  cohorts  and  have
been  the  precedent  for  some  commercial  genomic  tests,
providing  complementary  information  to  clinicians  in  order
to  obtain  a  more  precisely  classiﬁcation  patients  who  has
a  high  risk  of  recurrence,  and  to  offer  more  personalized
attention.
The  ﬁrst  commercial  signature,  and  the  one  still  widely
distributed  under  its  commercial  name,  is  MammaPrint®
(Agilent,  Amsterdam,  Holland).  This  signature  measures
mRNA  of  70  gene  expression  and  was  approved  by  the  US
FDA  and  by  regulators  in  the  EU  as  an  essay  with  prognostic
value  in  patients  with  BC  who  are  under  61  years  of  age,
in  an  I/II  stage,  with  negative  lymph  nodes  or  one  to  three
positive  lymph  nodes.  In  addition  to  accurately  identifying
patients  who  can  safely  avoid  adjuvant  chemotherapy.17,21
MammaPrint  stratiﬁes  patients  into  low-risk  or  high-risk
groups.17 However,  even  though  discrimination  is  good  for
ER+  cancers,  it  is  not  the  same  with  ER−  cancers,22,23
limiting  its  clinical  value  to  a  subgroup  of  patients.
Another  widely  distributed  and  commercially  available
assay  is  Oncotype  DX® test  (Genomic  Health,  Redwood  City,
CA,  U.S.).  This  test  is  used  to  classify  patients  with  Lumi-
nal  A  and  B  BCs,  as  well  as  HER2+  subtypes  (though  not
TNBC),  since  it  has  been  designed  to  assess  genes  related
to  ER,  proliferation  genes,  HER2  genes,  and  genes  related
to  invasion,  among  others.19 This  test  allows  the  oncolo-
gist  to  discern  whether  or  not  chemotherapy  treatment  will
be  beneﬁcial.  This  essay  measures  the  21-gene  expression,
which  provides  information  of  the  recurrence  of  the  disease
through  a  scoring  system  from  0  to  100,  stratifying  patients
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nto  low-risk  (score  <18),  intermediate  risk  (score  18--30)  or
igh  risk  (≥31)  groups.19,20
A  third  test,  consisting  of  an  algorithm  for  the  intrinsic
olecular  classiﬁcation  of  BC,  has  been  nominated  PAM50
Fig.  2).  This  was  designed  to  improve  IHC  and  microar-
ay  classiﬁcation  aggreance.24 This  50-gene  signature  can
lassify  BCs  as  luminal  A,  luminal  B,  HER2  and  basal-like.
he  PAM50  score  was  designed  with  the  purpose  of  trans-
ating  the  different  intrinsic  subtypes  into  an  associated
rognostic  value.24 An  application  of  this  score  is  the  iden-
iﬁcation  of  patients  who  may  beneﬁt  from  the  weekly
ddition  of  paclitaxel  to  conventional  chemotherapy  with
nthracycline  as  an  adjuvant  treatment  of  operable  BC  with
ositive  lymph  nodes.25 In  2013,  Prosigna  (Seattle,  Wash-
ngton,  U.S.)  started  commercializing  a  diagnostic  kit  which
ualiﬁes  mRNA  expression  of  the  50  genes  used  by  the  algo-
ithm  in  order  to  calculate  the  risk  of  recurrence.26
In  addition  to  these  tests,  which  are  the  most  commonly
istributed,  there  are  others  in  the  market,27--29 where  the
ommon  denominator  is  the  measurement  of  gene  expres-
ion  of  proliferation  related  genes.  It  is  important  to  mention
hat  these  multiple-gene  assays  are  for  the  most  part,  if  not
xclusively,  applicable  to  luminal  BC,  thus  stressing  once
ore  the  need  to  search  for  and  identify  markers  with  pro-
nostic  value  and  response  to  treatment  in  BC  patients  with
egative  hormonal  receptors  or  HER2  ampliﬁcation.
riple negative breast cancer (TNBC)
ince  1997,  the  National  Comprehensive  Cancer  Network
NCCN)  has  gathered  data  of  women  with  newly  diagnosed
reast  cancer,  representing  many  institutions  around  the
.S.  HER2  by  IHC’s  status  was  added  to  the  data  from  the
CCN  as  a routine  element  in  the  year  1999,  and  HER2  status
hrough  ﬂuorescent  in  situ  hybridization  (FISH)  was  added
n  2001.  The  term  ‘‘Triple  Negative  Breast  Cancer’’  (TNBC)
ppeared  for  the  ﬁrst  time  in  the  literature  in  2005.30 Due
o  the  lack  of  effective  therapeutic  options,  many  studies
ave  focused  on  the  understanding  of  the  biology  of  TNBC  for
he  selection  of  biomarkers  and  therapeutic  targets.  In  this
eview,  we  will  focus  on  making  a compilation  of  molecular
nd  gene  studies  in  reference  to  this  BC  subgroup.
NBC  risk  factors
NBC  makes  up  about  15--20%  of  all  BCs  and  follows  an
ggressive  clinical  course,  including  a high  incidence  of  vis-
eral  and  nervous  metastases,  compared  to  BCs  positive  to
ormone  receptors,  TNBC  is  more  frequently  associated  with
RCA1  and,  to  a  lesser  extent,  BRCA2  mutations.31,32 It  has
lso  been  associated  with  a  high  local  recurrence  rate  at
hree  years  after  treatment,  and  a high  death  rate  at  5  years.
pon  long-range  metastasis,  the  survival  rate  is  poor.33 Dif-
erently  from  other  subtypes  of  BC  (Luminal  A,  B  and  HER2),
here  early  pregnancy  has  been  recognized  as  a protective
actor  against  BC,  gestation  appears  to  be  an  important  risk
actor  in  the  development  of  the  triple  negative  phenotype.
n  a  study  by  Phipps  et  al.,34 they  reported  that  women  who
ad  more  children  (three  or  more)  had  a  greater  risk  (1.4
imes)  of  TNBC.  Later,  a  study  by  Tamimi  et  al.35 reafﬁrmed
108  G.I.  Uscanga-Perales  et  al.
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hat  multiple  pregnancies  were  associated  with  an  increased
isk  of  developing  TNBC.
Other  behaviors  associated  with  the  triple  negative  sub-
ype  are  a  lack  of  lactation,36 and  various  studies  have
ade  an  association  between  TNBC  and  a  high  body  mass
ndex  (BMI),  a  metabolic  syndrome,  type  2  diabetes,  obe-
ity  and/or  insulin  resistance.37--43 Consequently,  patients
ith  TNBC  are  the  group  with  the  worst  prognosis,  which
s  important  to  consider  in  a  country  like  Mexico,  which  has
n  elevated  prevalence  of  obesity  and  metabolic  syndrome.
Racial  ancestry  has  been  shown  to  have  an  important
elation  to  TNBC,  since  21%  of  Afro  American  BCs  have
een  classiﬁed  as  TNBC  (compared  to  15%  of  the  Caucasian
opulation).44--46 The  Hispanic  population  has  also  shown  a
igh  incidence  of  this  cancer  subtype,  with  a  frequency  of
1.3%  in  Peru,47 27%  in  Brasil,48 24.1%  in  Venezuela49 and
3.1%  in  Mexico.50
TNBC  presents  a  high  rate  of  proliferation51 and  is  highly
ggressive.32,52--54 In  a  study  by  Sorlie  et  al.,  in  which  the
esponse  to  an  uniform  treatment  was  evaluated,  they
eported  differing  results  between  patients  belonging  to
roups  of  distinct  subtypes.  Among  these  results  exist  a
eport  that  patients  with  TNBC  had  the  worst  prognosis  by
 signiﬁcant  margin  when  compared  to  patients  with  can-
ers  that  had  positive  hormone  receptors.11 In  a  later  study,
ent  et  al.  compared  the  clinical  history,  outcome  and  the
ature  of  the  disease  in  women  with  TNBC  to  women  with
ther  subtypes.  The  results  showed  that  TNBC  had  a  low
urvival  rate  and  a  high  rate  of  long-distance  metastasis
fter  treatment.52 Due  to  TNBC’s  aggressive  course,  these
ypes  of  cancers  can  be  highly  sensitive  to  cytotoxic  med-
cations.  The  proportion  of  patients  who  reach  a  completeation  example  using  PAM50.
athological  response  (CPR)  after  treatment  were  found  to
e  30--45%,55,56 and  the  patients,  which  achieved  a  CPR
ad  excellent  long-term  results,  with  a  global  survival  rate
igher  than  90%.  In  addition,  if  CPR  is  achieved,  patients
ith  TNBC  or  other  types  of  BC  had  a  similar  survival  rate.
owever,  those  patients  with  TNBC  who  presented  with  a
esidual  disease  had  worse  results  than  patients  with  other
ypes  of  BC.45,57 The  aggressiveness  of  TNBC  and  the  short-
ge  of  speciﬁc  therapeutic  options  underline  the  need  to
nderstand  the  ways  in  which  this  type  of  cancer  develops.
olecular  classiﬁcation  of  TNBC  subtypes
n  2007,  Kreike  et  al.  reported  that  TNBCs  were  synony-
ous  with  basal  type  molecular  cancers.58 However,  as  we
entioned  before,  it  has  been  proven  that  TNBC’s  molec-
lar  biology  is  diverse  and  heterogenous,59 and  that  TNBC
s  not  an  ideal  substitute  for  the  basal  phenotype.  In  2011,
ehmann  et  al.60 identiﬁed  6  subtypes  of  TNBC,  as  well  as
 unstable  subtype.  The  six  subtypes  included  two  basal
ike  (BL1  and  BL2),  one  immunomodulatory  class,  one  mes-
nchymal  class,  one  mesenchymal  stem  cell  (MSC)  class,  and
ne  luminal  androgen  receptor  (LAR)  class.  In  addition,  gene
xpression  analysis  allowed  the  authors  to  identify  the  cell
ines  representative  of  each  TNBC  subtype  to  later  evaluate
heir  response  to  different  medications.BLI:  Cancers  in  this  group  are  characterized  by  their  rapid
cell  division,  with  an  increased  proliferation  rate  and  loss
of  cell  cycle  control.  Due  to  this,  they  present  an  elevated
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expression  (mRNA)  of  Ki67  and  respond  to  antimitotic
agents.
BL2:  These  cancers  present  the  expression  of  EGFR,  TP63,
MET,  etc.  and  involve  activation  of  glycolysis  and  gluconeo-
genesis  routes.
IM:  They  are  composed  of  response  cells  from  the  immune
system,  and  present  antigens  and  cytokine  expression.
They  overlap  with  medullary  breast  cancer  with  a  favorable
prognosis.
M  and  MSL:  These  groups  present  epithelial-mesenchymal
transition  markers,  including  angiogenesis  (VEGFR2)  and
most  likely  respond  to  desatinib  (TK  inhibitors)  and  mTOR.
LAR:  This  group  is  characterized  by  the  expression  of
androgen  receptors  (AR).  They  are  RE  negative,  but
maintain  an  elevated  hormonal  component,  regulated  by
steroid  synthesis,  porphyrin  metabolism  genes  and  andro-
gens/estrogens.  The  AR’s  expression  is  up  to  nine  times
more  than  the  other  groups,  and  are  prime  candidates  for
anti-androgen  therapies.
The  signaling  pathways  obtained  by  the  study  are  poten-
tial  pharmacological  targets  in  these  cell  models  to  that
analysis  of  these  distinct  genetic  signatures  can  be  used  to
select  a  therapy.  In  general,  it  was  observed  that  the  BL1
and  BL2  subtypes  respond  well  to  cisplatin,  and  that  the
M  and  MSL  types  respond  well  to  NVP-BEZ235,  a  PI3K/mTOR
inhibitor  and  dasatinib  (a  tyrosine  kinase  inhibitor).  The  LAR
subtype  was  only  sensitive  to  bicalutamide  (an  androgen
receptor  agonist).
Later,  Burstein  et  al.61 conﬁrmed  four  of  the  subtypes
reported  by  Lehmann  with  the  base  DNA  proﬁles  or  the  sin-
gle  nucleotide  DNA  markers  from  198  TNBC  samples:  one
luminal  androgen  receptor  type,  one  mesenchymal  type,
and  two  basal  types.  These  studies  by  Burstein  and  Lehmann
suggested  the  existence  of  at  least  4  TNBC  subtypes
(Fig.  3).
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Cellular proliferation and 
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Figure  3  Lehman’s  triple  negative  breast  cancer  classiﬁcation,  gen
BL1, basal  like  1;  BL2,  basal  like  2;  IM,  immunomodulatory;  M,  me
luminal receptor;  MET,  mesenchymal  epithelial  transition.109
he  search  for  TNBC  biomarkers
arious  expression  studies  have  been  performed  on  TNBC
ith  the  aim  of  identifying  therapeutic  targets,  which  have
een  summarized  in  Table  1. This  summary  includes  the
haracteristics  of  each  study  and  the  selected  differentially
xpressed  principal  genes.  This  table  shows  the  variability  of
he  data  obtained  from  each  study.  This  indicates  that  vali-
ation  of  these  possible  molecular  targets  is  necessary  and
ven  more  studies  are  required  to  ﬁnd  efﬁcient  biomarkers
or  the  treatment  of  TNBC.
TNBC  is  a subtype  of  BC  with  a very  heterogeneous  behav-
or  which,  based  on  gene  expression  analysis  by  microarray,
as  classiﬁed  by  Lehmann  into  six  distinct  groups.  This  sub-
lassiﬁcation  is  not  only  useful  to  the  better  understanding
f  this  disease,  but  also  to  identify  new  molecular  targets
or  its  treatment.  Following  are  some  of  the  proteins  which
ave  been  identiﬁed  in  these  TNBC  groups  as  potential  ther-
peutic  targets.
EGFR:  This  is  one  of  the  principal  receptors,  and  plays  an
important  role  in  the  survival  of  the  tumor.  It  is  a  marker
of  cellular  proliferation,  angiogenesis,  metastasis  and  apo-
ptosis  inhibition.
VEGF:  This  is  the  principal  marker  for  angiogenesis.  It
induces  proliferation  and  maintains  the  integrity  of  the
cell.
C-kit  and  basal  cytokeratins:  C-kit  unites  with  the
receptor  of  a  growth  factor,  stimulates  survival  and  differ-
entiation,  and  induces  invasiveness  in  the  cancerous  cell.
The  basal  cytokeratins  are  intermediate  ﬁlament  proteins.
Their  expression  is  constant  when  epithelium  undergoes
transformation.
P53:  suppressor  protein  important  in  cell  cycle  regulation
and  tumor  apoptosis.
hKi67:  A  cellular  proliferation  marker  which  is  present  in
the  nucleus  during  interphase  and  mitosis.  Ki67  expression
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Table  1  Main  genes  reported  from  researches  which  analyze  TNBC  gene  expression  proﬁles.  TNBC,  triple  negative  breast  cancer;  nTNBC,  non-triple  negative  breast  cancer.
Author  Observation  Main  genes  Signature
objective
Experiment  design
Sample
characteristics
Comparison
Rody,  201159 16  meta-genes:  basal
phenotype,  androgen
receptor  signaling,
diverse  immune  cells,
stroma,  Claudine  CD24,
blood  cell  markers  and
adipocytes,
inﬂammation  and
angiogenesis  (VEGF)
EPHB3,  GABRP,  AR,  FOXA1,  IgG,  TCR,  LCK,  ITK,  HLA-DR,
-DM,  -DP,  -DQ,  HLA-A,  -B,  -C,  -E,  -F,  -G,  OAS1,  OAS2,
OAS3, MX1,  Decorin,  Osteonectin,  Fibronectin.
COL5A1,  CLDN3,  CLDN4,  CD24,  ELF3,  BUB1,  CDC2,  STK6,
BIRC5,  TOP2A,  HBA1,  HBA2,  HBB,  FABP4,  PLIN,  ADIPOQ,
ADH1B,  VEGF,  adrenomedulina,  ANGPTL4,  IL-8,  CXCL1,
CXCL2,  HOXA-4,  -5,  -7,  -9,  -10,  -11,  Histones  H2A,  H2B
Prognosis/
therapeutic  target
Public  database  394  TNBC
Karn, 201171 2  signatures  (26  main
genes)
IL8,  SCD,  AQP3,  SERPINE1,  LYPDC1,  PGK1,  SEC23A,
SNAPC1,  SNF7DC2,  SORT1,  SPOCK,  SRPX2,  STC1,  STMN2,
SYNCRIP,  TAX1BP3,  TBC1D22B,  TGFB2,  TGFBI,  THBS1,
TIAM1,  TLE6,  TNFAIP1,  TNFRSF10B,  TRIM23,  TSGA10,
TXNDC9,  U2AF1L1,  ULBP2,  UQCRC1,  VLDLR,  VMD2,
WFDC1,  WWTR1,  ZA20D1,  ZP2
Prognosis  Public  database  394  TNBC
Cascione, 201372 2×  microRNA  signatures
and  4  gene  subgroups
miR-16,  155,  125b,  374a  and  miR-16,  125b,  374a,  374b,
421, 655,  497
Molecular  subgroup  1:  SPP1,  MMP9,  MYB12,  BIRC5,
TOP2A,  CDC2,  CDKN2A.  Molecular  subgroup  2:  BCL2,
EGF,  ERBB4,  AR,  ESR1,  IL1A,  FGFR2,  WT1,  MYC,  FGF2,
AKT1,  CASP10.  Molecular  subgroup  3:  MET,  L1CAM,
IGFBP3.  Molecular  subgroup  4:  TIMP1,  TIMP2,  CDKN1A,
CCND2,  MAP3K8,  CAV1,  LAMB1,  JUN,  CEBPA
Sub-classiﬁcation/
therapeutic  target
Parafﬁn-
embedded
tissue
TNBC  vs  Adjacent
tissue  and  lymph
node  injuries
Komatsu, 201373 322  unregulated  genes  Main  overexpressed  genes:  UBE2C,  S100P,  UCHL1,
PTTG1,  UBE2T,  SIX1,  PRC1,  TOP2A,  HORMAD1,  FABP5,
ATAD2.  Main  sub-expressed  genes:  PIP,  DNAL11,  WIF1,
SCUBE2,  TBC1D9,  TFF3,  ERBB4,  GATA3,  MLPH.  LAMAB,
LTBP2,  LIFR,  LRP2,  MASP2,  MATN2,  MGP,  NTN4,  NRG1,
PTHLH,  PI15,  PLAT,  PDGFA,  PTN,  PIGR,  PIP,  SCGB1D1,
SCGB1D2,  SCGB3A1,  SEMA3G,  STC2,  THSD4,  TFF3.
Therapeutic  target  Fresh  tissue  TNBC  vs  epithelial
ductal  cells
Al-Ejeh, 201474 8  genes  MAPT,  MYB,  MELK,  MCM10,  CENPA,  EXO1,  TTK  and  KIF2C  Prognosis/
therapeutic  target
Meta-analysis  CMTN  vs  CMnTN
Khaled, 201575 1  gene  BCL11A  Therapeutic  target  Public  data
base
CMTN  vs  CMnTN
He, 201576 3  genes  DUSP1  and  FOXA1.  DUSP1  Therapeutic
targets
Public  data
base
CMTN  vs  CMnTN
Pacheco-Velazquez,
201477
4  genes  HIF-1  +  c-MYC  +  2OGDH  +  E-cadherina  Prognosis  Fresh  tissue  CMTN  vs  CMnTN  vs
Normal  tissue
••
•
•
•
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in  normal  mammary  tissue  is  <3%.  The  expression  of  TNBC
can  elevate  it  up  to  80%.  It  self-expresses  particularly  in
RE-negative  cells.  It  is  associated  with  an  unfavorable  prog-
nosis.
PARP:  A  family  of  cell  signaling  enzymes.  18  PARP  pro-
teins  have  been  identiﬁed.  PARP1  is  responsible  for  the
majority  of  its  functions.  It  is  a  DNA  damage  sensor  and
plays  an  important  role  in  its  repair  and  in  responses  to
inﬂammation,  ischemia  and  oxidative  stress.  In  cells  with
a  BRCA  mutation,  PARP  inhibition  contributes  to  cell  death
by  apoptosis.
Hsp90:  A  cellular  chaperone,  it  stabilizes  the  conformation
of  many  labile  proteins,  such  as  steroid  receptors,  CDK4,
RAF-1  and  AKT,  etc.  PU-H71  is  a  cyclin  inhibitor  which  has
been  shown  to  be  useful  in  some  TNBC  models.
COX2:  This  protein  is  expressed  by  the  inﬂammatory  stim-
ulus  and  its  expression  is  associated  with  an  unfavorable
prognosis.
TK:  A  regulatory  protein  which  helps  the  cell  grow  and
differentiate  itself.
mTOR:  The  over-expression  of  these  proteins  (PI3K/mTOR)
is  associated  with  a  poor  response  to  treatment  with  hor-
mones  and  trastuzumab.
TNBC  treatment
Women  with  TNBC  are  not  able  to  take  endocrinology
therapies  neither  HER2  targeted  therapies,  hence  treat-
ment  options  are  limited  to  surgery,  radiotherapy  and
chemotherapy,62,63 being  chemotherapy  the  standard  treat-
ment  of  TNBC.  In  the  past  two  decades  the  use  of  more
aggressive  therapy  has  produced  a  clearer  improvement
in  quality  of  life;  however,  there  is  a  consensus  opinion,
which  considers  that  it  would  be  impossible  to  improve  these
results  if  this  cytotoxic  therapy  remained  the  only  option  to
be  offered  to  these  patients.  For  this  reason,  there  is  an  urge
to  ﬁnd  new  ‘‘intelligent  drugs’’  capable  of  solving  chemore-
sistance  and  reducing  the  risks  of  chemotherapy  in  patients
who  do  respond.  The  greatest  obstacle  to  ﬁnd  actionable
targets  is  the  vast  heterogeneity  both  inter  and  intra-tumor
of  the  TNBC.  In  fact,  several  years  of  study  have  failed  to
prove  a  uniﬁed  alteration  which  may  serve  as  targets  of  a
targeted  therapy.
Several  researches  about  TNBC  describe  genomic  sig-
natures  involving  affected  signaling  pathways,  including
cellular,  immunologic  and  metabolic  processes  like  --  basal
keratin  differential  expressions,  interferon  proliferation  and
regulation  routes,  low  expression  in  Claudine,  mesenchy-
mal  epithelial  transition,  androgen  receptor  expression
(AR)  and  angiogenesis  activation  (VEGF).58--60 These  ﬁndings
have  revealed  potential  molecular  targets,49 and  different
drug  types  are  currently  found  under  investigation,  which
can  basically  be  deﬁned  in  four  groups:  (1)  agents  which
cause  damage  to  DNA  (i.e.  cisplatin,  cyclophosphamide),
(2)  agents  which  inhibit  poly  (ADP-ribose)  polymerase
(PARP  inhibitors),  (3)  tyrosine-kinase  inhibitors  and  (4)
agents  which  inhibit  downstream  signaling  pathways  (mainly
PI3K/AKT).64 Down  below  there  are  the  descriptions  of  treat-
ments  which  have  been  proven  depending  upon  identiﬁed
therapeutic  targets  in  TNBC.
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 Bevacizumab:  Anti-VEGF  (vascular  endothelial  growth
factor)  monoclonal  antibody  that  blocks  angiogenesis;
although,  a  lack  of  efﬁciency  as  well  as  a  toxicity  incre-
ment  have  been  observed.65
 Olaparib/iniparib:  PARP  inhibitors  in  patients  with  muta-
tions  in  BRCA1/2,  they  have  also  been  widely  studied
since  they  have  shown  to  have  anticancer  selective  activ-
ity  in  BRCA1  and  BRCA2-deﬁcient  cancers;  nevertheless,
the  relevance  of  the  inhibition  of  these  enzymes  has  yet
to  be  conﬁrmed.66
 Cetuximab:  Anti-EGFR  monoclonal  targeted  antibody,  it
has  been  evaluated  as  monotherapy  or  with  a  platinum-
based  therapy  (carboplatin).  Even  though,  at  ﬁrst,  this
therapy  seemed  to  be  very  promising,  it  has  proven  very
modest  results.67
 mTOR  inhibitors  (mammalian  target  of  rapamycin)  --
mTOR  is  a  PI3K  signaling  pathway  effector  regulated  by
AKT  and  suppressor  of  PTEN  tumors.  PI3K  pathway  pro-
teins  are  frequently  affected  by  mutations  in  mammary
carcinomas,  and  the  loss  of  PTEN  is  a  frequent  discovery
in  TNBC;  thus,  increasing  the  activation  of  mTOR  in  the
diseases.68 It  is  for  this  reason  that  today,  mTOR  inhibitor
drugs  have  been  under  evaluation.69
 Bicalutamide/enzalutamide  (‘‘anti-androgen’’  targeted
therapy):  Some  preclinical  studies  showed  that  lumi-
nal  TNBC  which  expresses  the  androgen  receptor  (AR)
is  sensitive  to  androgen  deprivation.  Bicalutamide  as
monotherapy  demonstrated  a  clinical  beneﬁt  of  19%  of  the
AR  positive.70 Today,  a  phase  II  study  is  evaluating  enza-
lutamide’s  safety  and  efﬁcacy  in  TNBC  and  AR  positive
patients.  Results  are  yet  to  be  seen.
Targeted  therapies  against  some  identiﬁed  biomarkers  in
NBC  have  not  proven  a  signiﬁcant  improvement,  the  prob-
em  has  been  the  lack  of  dependable  predictive  biomarkers,
hich  is  essential  before  any  of  these  treatments  can  be
ntroduced  in  clinical  practice.
onclusions
NBC  is  usually  the  most  aggressive  type  of  cancer  and  it  is
inked  to  the  highest  mortality  rate  in  comparison  to  other
ypes  of  BC.  Numerous  advances  in  the  understanding  of  this
ancer  have  been  made.  Reported  genomic  signatures  to
ate  reﬂect  the  heterogeneity  of  the  triple  negative  pheno-
ype,  at  the  same  time  have  allowed  for  a  TNBC  classiﬁcation
nto  6  clinically  relevant  subgroups.  One  of  these  subgroups
as  a  strongly  immune  component.  Another  subgroup  shares
iological  characteristics  with  mutations  in  genes  BRCA1/2
ith  deﬁciency  in  DNA  repair.
While  several  TNBC  biomarkers  are  reported  in  the  lit-
rature  every  year,  only  few  have  exceeded  validation  to
ustify  its  use  in  clinical  practice.  The  reason  for  this  deteri-
ration  may  be  due  to  the  fact  that  while  strong  associations
ften  derive  initially  between  the  expression  of  a putative
iomarker  and  the  stage  of  the  disease,  candidate  markers
o  not  often  have  any  relevant  and  signiﬁcant  functions  of
he  disease  in  clinical  laboratory  and  therapeutic  practice.
or  TNBC  speciﬁcally,  different  research  groups  that  used
he  information  generated  by  microarrays  obtained  results
arying  from  one  group  to  another  and  in  some  cases  these
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esults  have  not  been  able  to  be  validated.  This  could  be  a
esult  of  the  inherent  heterogeneity  of  TNBC  or  each  exper-
ment  design’s  own  limitations,  such  as:  (1)  the  use  of  large
ata  base  retrospective  cohorts,  where  TNBC’s  classiﬁcation
s  based  solely  on  the  information  obtained  from  the  gene
xpression  proﬁle  data,  this  methodology  is  not  the  standard
n  clinical  practice.  Also,  this  information  shows  limita-
ions  due  to  how  varying  the  data  collection  and  sample
anagement  methods  are  used  (in  some  cases  parafﬁn-
mbedded  tissue  was  utilized,  others  utilized  fresh  tissue,
tc.)  to  feed  the  databases  that  are  afterwards  referenced
y  other  researchers;  (2)  limited  gene  expression  analysis
f  a  determined  number  of  genes,  instead  of  conducting  a
lobal  analysis  of  gene  expression;  (3)  previous  works  and
esearches  compared  TNBC  gene  expression  proﬁles  vs  other
C  subtypes,  or  TNBC  vs  normal  tissue,  which  does  not  unify
tratiﬁcation  criteria.
In  Mexico,  there  are  few  research  papers  which  report
he  analysis  of  TNBC  expression  proﬁles  This  is  concerning,
ince  this  type  of  BC  jeopardizes  a  considerable  amount  of
ases  among  the  Mexican  population,  hence  it  is  necessary
o  increase  efforts  in  the  search  of  biomarkers  or  possible
herapeutic  targets  which  can  be  validated  in  our  popula-
ion.
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